drugset / Trial / NCT05323487
Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
Phase 1
Recruiting
75 enrolled
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedSequentialTriple-blindOther
Summary
This study will employ a randomized order, double-blind, repeated measures dose ranging design. This design was chosen in order to generate multiple within-subject serial loop diuretic dose response exposures. The overall study schema will include 75 heart failure (HF) patients.
Timeline
- Start
- 2022-06-01
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bumetanide | Small molecule | 1.25 mg | Intravenous |
| Comparator | Bumetanide | Small molecule | 2.5 mg | Intravenous |
| Comparator | Bumetanide | Small molecule | 5 mg | Intravenous |
| Comparator | Bumetanide | Small molecule | 10 mg | Intravenous |